Jane Huang, CMO, Hematology at BeiGene, Ltd. (BGNE), sold 18,701 shares at $362.80 ($6.7M) on 2021-09-13, disclosed to the SEC on 2021-09-15.
Seasonal sale ($6.7M) by CMO, Hematology — this insider has traded BGNE in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $355.37 | 4,219 | $1.5M | 22.4% |
| 2 | $355.37 | 4,219 | $1.5M | 22.4% |
| 3 | $356.46 | 1,400 | $499K | 7.5% |
| 4 | $357.54 | 1,300 | $465K | 6.9% |
| 5 | $359.15 | 1,700 | $611K | 9.1% |
| 6 | $359.88 | 1,800 |
| $648K |
| 9.7% |
| 7 | $361.05 | 900 | $325K | 4.9% |
| 8 | $362.80 | 1,581 | $574K | 8.6% |
| 9 | $362.80 | 1,581 | $574K | 8.6% |
| 10 | $363.45 | 1 | $363 | 0.0% |
| Total | $357.91 avg | 18,701 | $6.7M | 100% |
| Filing → |
| BGNE | SELL | 2021-12-02 | $755K | — | Filing → |
| BGNE | SELL | 2021-11-19 | $572K | — | Filing → |
| BGNE | SELL | 2021-10-21 | $559K | — | Filing → |